Literature DB >> 31778540

Cardiovascular adverse events of ibrutinib.

Inhye E Ahn.   

Abstract

Entities:  

Mesh:

Substances:

Year:  2019        PMID: 31778540      PMCID: PMC6887111          DOI: 10.1182/blood.2019002805

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


× No keyword cloud information.
  10 in total

1.  Ibrutinib Regimens versus Chemoimmunotherapy in Older Patients with Untreated CLL.

Authors:  Jennifer A Woyach; Amy S Ruppert; Nyla A Heerema; Weiqiang Zhao; Allison M Booth; Wei Ding; Nancy L Bartlett; Danielle M Brander; Paul M Barr; Kerry A Rogers; Sameer A Parikh; Steven Coutre; Arti Hurria; Jennifer R Brown; Gerard Lozanski; James S Blachly; Hatice G Ozer; Brittny Major-Elechi; Briant Fruth; Sreenivasa Nattam; Richard A Larson; Harry Erba; Mark Litzow; Carolyn Owen; Charles Kuzma; Jeremy S Abramson; Richard F Little; Scott E Smith; Richard M Stone; Sumithra J Mandrekar; John C Byrd
Journal:  N Engl J Med       Date:  2018-12-01       Impact factor: 91.245

2.  Ibrutinib for patients with relapsed or refractory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study.

Authors:  Susan O'Brien; Jeffrey A Jones; Steven E Coutre; Anthony R Mato; Peter Hillmen; Constantine Tam; Anders Österborg; Tanya Siddiqi; Michael J Thirman; Richard R Furman; Osman Ilhan; Michael J Keating; Timothy G Call; Jennifer R Brown; Michelle Stevens-Brogan; Yunfeng Li; Fong Clow; Danelle F James; Alvina D Chu; Michael Hallek; Stephan Stilgenbauer
Journal:  Lancet Oncol       Date:  2016-09-13       Impact factor: 41.316

Review 3.  The risk of atrial fibrillation with ibrutinib use: a systematic review and meta-analysis.

Authors:  Darryl P Leong; François Caron; Christopher Hillis; Annie Duan; Jeff S Healey; Graeme Fraser; Deborah Siegal
Journal:  Blood       Date:  2016-05-31       Impact factor: 22.113

Review 4.  2017 ACC/AHA/AAPA/ABC/ACPM/AGS/APhA/ASH/ASPC/NMA/PCNA Guideline for the Prevention, Detection, Evaluation, and Management of High Blood Pressure in Adults: Executive Summary: A Report of the American College of Cardiology/American Heart Association Task Force on Clinical Practice Guidelines.

Authors:  Paul K Whelton; Robert M Carey; Wilbert S Aronow; Donald E Casey; Karen J Collins; Cheryl Dennison Himmelfarb; Sondra M DePalma; Samuel Gidding; Kenneth A Jamerson; Daniel W Jones; Eric J MacLaughlin; Paul Muntner; Bruce Ovbiagele; Sidney C Smith; Crystal C Spencer; Randall S Stafford; Sandra J Taler; Randal J Thomas; Kim A Williams; Jeff D Williamson; Jackson T Wright
Journal:  Hypertension       Date:  2017-11-13       Impact factor: 10.190

5.  Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes.

Authors:  Jason A Dubovsky; Kyle A Beckwith; Gayathri Natarajan; Jennifer A Woyach; Samantha Jaglowski; Yiming Zhong; Joshua D Hessler; Ta-Ming Liu; Betty Y Chang; Karilyn M Larkin; Matthew R Stefanovski; Danielle L Chappell; Frank W Frissora; Lisa L Smith; Kelly A Smucker; Joseph M Flynn; Jeffrey A Jones; Leslie A Andritsos; Kami Maddocks; Amy M Lehman; Richard Furman; Jeff Sharman; Anjali Mishra; Michael A Caligiuri; Abhay R Satoskar; Joseph J Buggy; Natarajan Muthusamy; Amy J Johnson; John C Byrd
Journal:  Blood       Date:  2013-07-25       Impact factor: 22.113

6.  Ibrutinib Inhibits ERBB Receptor Tyrosine Kinases and HER2-Amplified Breast Cancer Cell Growth.

Authors:  Jun Chen; Taisei Kinoshita; Juthamas Sukbuntherng; Betty Y Chang; Laurence Elias
Journal:  Mol Cancer Ther       Date:  2016-09-27       Impact factor: 6.261

7.  Hypertension and incident cardiovascular events following ibrutinib initiation.

Authors:  Tyler Dickerson; Tracy Wiczer; Allyson Waller; Jennifer Philippon; Kyle Porter; Devin Haddad; Avirup Guha; Kerry A Rogers; Seema Bhat; John C Byrd; Jennifer A Woyach; Farrukh Awan; Daniel Addison
Journal:  Blood       Date:  2019-11-28       Impact factor: 22.113

8.  Long-term follow-up of the RESONATE phase 3 trial of ibrutinib vs ofatumumab.

Authors:  John C Byrd; Peter Hillmen; Susan O'Brien; Jacqueline C Barrientos; Nishitha M Reddy; Steven Coutre; Constantine S Tam; Stephen P Mulligan; Ulrich Jaeger; Paul M Barr; Richard R Furman; Thomas J Kipps; Patrick Thornton; Carol Moreno; Marco Montillo; John M Pagel; Jan A Burger; Jennifer A Woyach; Sandra Dai; Remus Vezan; Danelle F James; Jennifer R Brown
Journal:  Blood       Date:  2019-03-06       Impact factor: 25.476

9.  Single-agent ibrutinib in treatment-naïve and relapsed/refractory chronic lymphocytic leukemia: a 5-year experience.

Authors:  Susan O'Brien; Richard R Furman; Steven Coutre; Ian W Flinn; Jan A Burger; Kristie Blum; Jeff Sharman; William Wierda; Jeffrey Jones; Weiqiang Zhao; Nyla A Heerema; Amy J Johnson; Ying Luan; Danelle F James; Alvina D Chu; John C Byrd
Journal:  Blood       Date:  2018-02-02       Impact factor: 25.476

10.  Sustained efficacy and detailed clinical follow-up of first-line ibrutinib treatment in older patients with chronic lymphocytic leukemia: extended phase 3 results from RESONATE-2.

Authors:  Paul M Barr; Tadeusz Robak; Carolyn Owen; Alessandra Tedeschi; Osnat Bairey; Nancy L Bartlett; Jan A Burger; Peter Hillmen; Steven Coutre; Stephen Devereux; Sebastian Grosicki; Helen McCarthy; Jianyong Li; David Simpson; Fritz Offner; Carol Moreno; Cathy Zhou; Lori Styles; Danelle James; Thomas J Kipps; Paolo Ghia
Journal:  Haematologica       Date:  2018-06-07       Impact factor: 9.941

  10 in total
  1 in total

Review 1.  Cardiotoxicity of Novel Targeted Hematological Therapies.

Authors:  Valentina Giudice; Carmine Vecchione; Carmine Selleri
Journal:  Life (Basel)       Date:  2020-12-11
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.